MEDINET Co., Ltd.
Notice Regarding Cessation of Domestic Development in Japan for a Regenerative Medicine Product That Received Manufacturing and Marketing Approval in India
Announces cessation of domestic development of MDNT-03. Reassesses resource allocation for the regenerative medicine business and prioritizes management resources toward the cell processing business. Will consider continuing domestic development through external partnerships. No impact on the fiscal year ending September 2026 results.
Key Figures
- Decision to discontinue domestic development due to cessation of MDNT-03 development in Japan (figures unknown)
- Increased allocation of investment to the cell processing business (ratio/amount unknown)
- No impact on the fiscal year ending September 2026 results (conclusion)
AI要約
Key Points
Decided to discontinue domestic development in Japan of MDNT-03 (Stempeucel®). To improve profitability and strengthen the financial base, the company will reinforce resource allocation to the cell processing business. While regenerative medicine-related development will remain under continuous consideration, the company will explore possibilities to continue domestic development through partnerships with third parties or business transfers. There are no concerns regarding quality or safety.
Outlook and Impact
The cessation of MDNT-03 will have no impact on the fiscal results for the year ending September 2026. Reflection in performance forecasts for the fiscal year ending September 2027 and beyond will be considered. The company will promptly disclose any matters that should be announced. It will continue to strengthen the technological foundation in the cell processing field and pursue future regenerative medicine-related development opportunities.
MEDINET Co., Ltd.
Company overview · Stock price · Financial data · All IR
